SCHEMBL214574

SCHEMBL214574

Cc1ccc(Br)cc1-n1cnc(C(N)=O)c1C(=O)Nc1ccc(Cl)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.41
▸ MEN1 O00255 6/20 0.41
▸ KMT2A Q03164 6/20 0.41
▸ SMN1; SMN2 Q16637 4/20 0.41
▸ NPC1 O15118 4/20 0.41
▸ HTT P42858 2/20 0.41
▸ FLT1 P17948 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ GRM4 Q14833 3/20 0.39
▸ MAPT P10636 4/20 0.38
▸ POLB P06746 3/20 0.38
▸ TP53 P04637 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ GBA1 P04062 1/20 0.38
▸ LMNA P02545 3/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL215228 0.90 SCN9A (0.44) RAB9AMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL215824 0.90 RAB9A (0.41) RAB9AMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL213975 0.88 KMT2A (0.42) RAB9AMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL215330 0.87 ALDH1A1 (0.46) RAB9AMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL214245 0.86 NPC1 (0.41) RAB9AMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL215860 0.86 MEN1 (0.38) RAB9AMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL213700 0.85 SORT1 (0.46) RAB9AMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL214745 0.84 KMT2A (0.41) RAB9AMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL215374 0.81 ABL1 (0.37) RAB9AMEN1KMT2ANPC1MAPT
SCHEMBL214660 0.80 SIK1 (0.33) RAB9AMEN1KMT2AMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 — — US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 — — US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 — — EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 RAB9A 2213/4885MEN1 3504/4885KMT2A 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback